The Infectious Disease Diagnostics Market has become a cornerstone of modern healthcare, helping doctors identify life-threatening conditions quickly and accurately. Valued at USD 44.93 billion in 2024, the market is projected to expand from USD 46.59 billion in 2025 to USD 62.26 billion by 2033, growing at a CAGR of 3.69% during the forecast period.
? Download Sample Report
As infectious diseases continue to rise worldwide, demand for fast and reliable diagnostic solutions has surged. From traditional laboratory tests to advanced point-of-care (POC) devices, innovations in diagnostics are improving outcomes and reducing strain on healthcare systems.
Market Drivers
Several factors are fueling the growth of the infectious disease diagnostics market:
Rising Prevalence of Infectious Diseases
Infectious diseases such as tuberculosis, HIV, hepatitis, and hospital-acquired infections are on the rise globally. The CDC reported 7,174 new tuberculosis cases in the U.S. in 2020, while Salmonella causes approximately 1.35 million infections annually. These alarming statistics underscore the need for early detection and accurate diagnosis.Technological Advancements and Point-of-Care Testing
Traditional diagnostic methods can be slow and less accurate. This has paved the way for rapid, portable, and precise point-of-care kits. These devices provide immediate results and improve disease management, especially in underserved regions.Hospital-Acquired Infections on the Rise
Healthcare-associated infections such as central line bloodstream infections and ventilator-associated events increased significantly between 2019 and 2020. With a growing geriatric population and higher hospital admissions, demand for diagnostics in hospitals is projected to accelerate.Global Research and Development Efforts
Governments and research bodies are investing heavily in diagnostics. For example, India’s Department of Biotechnology supports projects on viral, bacterial, and fungal diseases, promoting innovation in diagnostic tools and technologies.
Market Restraints
Despite rapid growth, challenges persist. High healthcare costs and limited access to advanced diagnostic tools in developing regions restrict adoption. Many rural clinics lack modern equipment, limiting the reach of novel diagnostic technologies.
Market Opportunities
One of the most promising opportunities lies in decentralized diagnostics and remote sample collection. Advances in telemedicine and virtual care models allow patients to undergo testing without visiting hospitals. This not only enhances convenience but also drives compliance, especially in regions with limited infrastructure.
Regional Insights
North America dominates the market, with the U.S. showing strong demand due to rising infectious diseases, rapid adoption of POC testing, and technological innovation.
Europe is growing at a CAGR of 4.06%, with Germany leading through government initiatives such as community-based HIV testing programs.
Asia Pacific shows immense potential, particularly China, where 1.71 million infectious disease cases were reported in December 2019. New approvals like the QuantiFERON-TB Gold Plus test further strengthen market prospects.
Gulf Cooperation Council (GCC) nations are seeing rising tuberculosis cases, boosting demand for diagnostic solutions.
Brazil faces a high prevalence of hepatitis C, creating significant opportunities for diagnostic companies.
Application Insights
Hospital-acquired infections lead the market with a projected CAGR of 5.33%, driven by an aging population and increasing hospital visits.
Hepatitis diagnostics are expanding rapidly, supported by government initiatives such as the U.S. Viral Hepatitis National Strategic Plan (2021–2025).
Product Insights
Assays, kits, and reagents dominate the market, growing at a CAGR of 3.95%. The surge in demand for reagents during the COVID-19 pandemic significantly contributed to this segment.
Diagnostic instruments and software services continue to expand, supported by growing R&D in microbiology and POC testing.
Technology Insights
Immunodiagnostics hold the largest share, growing at a CAGR of 3.79%. These tests rely on antigen-antibody reactions and are widely used in hospitals and labs.
Polymerase Chain Reaction (PCR) remains a vital technology, with advancements in high-throughput and microfluidics-based PCR systems boosting adoption.
Key Players in the Infectious Disease Diagnostics Market
Prominent companies driving innovation and expansion include:
Biomerieux Inc.
Abbott Laboratories
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
Quidel Corporation
Diasorin Spa (Luminex Corporation)
Trinity Biotech Plc
Quest Diagnostics
Sysmex Corporation
Ortho-Clinical Diagnostics
Seegene Inc.
These players focus on product launches, mergers, and collaborations to strengthen their presence globally.
Recent Developments
January 2023: Precigen, Inc. announced positive Phase 1 results for its PRGN-2012 immunotherapy for recurrent respiratory papillomatosis.
January 2023: Memo Therapeutics AG reported favorable Phase 1 safety data for AntiBKV, targeting BK polyomavirus in renal transplant patients.
Conclusion
The infectious disease diagnostics market is set for steady growth, driven by rising disease prevalence, technological innovations, and decentralized testing models. With strong opportunities across regions and continuous product development, stakeholders can expect sustainable expansion through 2033.
About Straits Research Pvt. Ltd.
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI. Whether you are looking at business sectors in the next town or across continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
? Phone: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
? Email: sales@straitsresearch.com
